Xuan Wang

Xuan Wang

Auto-generated profile, based on publicly available information

Xuan Wang

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
HLHongrui Li
Hongrui Li
XWXianyun Wang
Xianyun Wang
XLXiaoying Li
Xiaoying Li
XZXueyang Zhou
Xueyang Zhou
XWXuan Wang
Xuan Wang
YXYuan-Di Xi
Yuan-Di Xi
Li H, et al. Nutr Res Pract. 2023 Apr;17(2):371-385. https://doi.org/10.4162/nrp.2023.17.2.371

1 January 2025 in Stroke
Verified
Journal Article
Closed access
YZYanli Zhang
Yanli Zhang
XWXuan Wang
Xuan Wang
YGYing Gao
Ying Gao
WCWeiqi Chen
Weiqi Chen
SJS. Claiborne Johnston
S. Claiborne Johnston
YPYuesong Pan
Yuesong Pan
BACKGROUND: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile. METHODS: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022. Patients were stratified into different groups based on the Essen Stroke Risk Score (ESRS) and modified ESRS. The primary efficacy outcome was any new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding within 90 days. RESULTS: Among 6100 patients (3050 each in the clopidogrel-aspirin group and aspirin group), the median age was 65 years (interquartile range, 57–71 years), and 3915 (64.2%) were male. Clopidogrel-aspirin was associated with a reduced risk of new stroke in patients with an ESRS of <3 (hazard ratio [HR], 0.67 [95% CI, 0.52–0.86]), but not in those with an ESRS of ≥3 (HR, 0.92 [95% CI, 0.72–1.18]), compared with aspirin ( P interaction =0.07). Similar results were found in patients stratified by modified ESRS (modified ESRS <6 in male and <5 in female: HR, 0.68 [95% CI, 0.55–0.83]; modified ESRS ≥6 in male and ≥5 in female: HR, 1.14 [95% CI, 0.82–1.59]; P interaction =0.01). The association between antiplatelet therapy and the moderate-to-severe bleeding did not differ across risk profile subgroups (ESRS of <3: HR, 1.35 [95% CI, 0.54–3.35]; ESRS of ≥3: HR, 3.21 [95% CI, 1.18–8.78]; P interaction =0.21; modified ESRS of <6 in male and <5 in female: HR, 1.96 [95% CI, 0.88–4.36]; modified ESRS of ≥6 in male and ≥5 in female: HR, 2.27 [95% CI, 0.70–7.39]; P interaction =0.85). CONCLUSIONS: This post hoc analysis of the INSPIRES trial showed that patients with a low level of risk profile assessed by ESRS received greater benefit from clopidogrel-aspirin initiated within 72 hours after symptom onset than aspirin alone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03635749.

15 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
YWYicong Wang
Yicong Wang
YPYuesong Pan
Yuesong Pan
XWXuan Wang
Xuan Wang
YGYing Gao
Ying Gao
WCWeiqi Chen
Weiqi Chen
YWYilong Wang
Yilong Wang
Background: Inflammation is an important mechanism in ischemic stroke and high‐risk transient ischemic attack, but clinical inflammatory markers on antiplatelet therapy remain to be studied. This study was designed compare the neutrophil count (NC) on the efficacy and safety of clopidogrel–aspirin with that of aspirin in patients with ischemic stroke or high‐risk transient ischemic attack caused by intracranial or extracranial atherosclerosis. Methods: The INSPIRES (Intensive Statin and Antiplatelet Therapy for High‐Risk Intracranial or Extracranial Atherosclerosis) study was a post hoc analysis of the multicenter, randomized, double‐blind, placebo‐controlled, 2‐by‐2 factorial trial. The primary efficacy and safety outcomes were 90‐day stroke and moderate‐to‐severe bleeding. The differences in the efficacy outcome were calculated with cox proportional hazards model and the generalized linear model as well as logistic regression. Results: The study included 5929 patients of median age 65 years (interquartile range, 57–71 years), 3800 (64.09%) of whom were men; 1983 (33.45%) had a low NC (≤3.65×10 9 /L), 1973 (33.28%) had an intermediate NC (3.654.97×10 9 /L). Patients with ischemic stroke or transient ischemic attack with a higher NC benefited more from clopidogrel–aspirin than from aspirin alone. There was no significant difference in the primary safety outcome of moderate‐to‐severe bleeding according to antiplatelet therapy or NC. Conclusions: The post hoc analysis suggested patients with a higher NC obtained greater benefit from clopidogrel–aspirin than from aspirin without an increase in bleeding risk. The findings may serve as a reference indicator for future anti‐inflammatory therapy. However, further research is needed to explore the mechanism.

2 September 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
LZLijun Zuo
Lijun Zuo
ZKZaylea Kua
Zaylea Kua
XWXuan Wang
Xuan Wang
ALAudrey Low
Audrey Low
XCXueli Cai
Xueli Cai
YPYuesong Pan
Yuesong Pan
Background: Sex affects the prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors but whether sex differences exist in the associations between ASCVD risk burden and cognitive function is unclear. Methods: This cross‐sectional study included participants from a population‐based cohort study in China that recruited community‐dwelling adults aged 50 to 75 years without baseline cardiovascular disease and stroke. The 10‐year ASCVD risk burden was quantified with 3 multivariate risk prediction equations. Cognitive domains of memory, attention, visuospatial function, executive function, and processing speed were assessed. Multivariable linear regression models were used to examine the interaction terms between sex and ASCVD risk scores on cognition. Results: The final analytical sample included 2180 participants. Mean±SD age was 60.14 (6.38) and 52.1% were women. Men showed significantly higher ASCVD risk burden than women at baseline but the effect of ASCVD risk on 2‐year cognition were amplified in women compared with men, for the domains of memory (eg, β=−0.20 [95% CI, –0.26 to −0.13] versus β=−0.11 [95% CI, –0.16 to −0.07]), executive function (eg, β=−0.23 [95% CI, –0.31 to −0.16] versus β=−0.16 [95% CI, –0.21 to −0.10]), and processing speed (eg, β=−0.33 [95% CI, –0.39 to −0.27] versus β=−0.17 [95% CI, –0.21 to −0.13]). Sex‐stratified analyses showed different neuropsychological profiles at moderate ASCVD risk burden levels, suggesting sex‐specific ASCVD‐risk related cognitive phenotypes. Conclusions: Sex differences in cognitive health affected by ASCVD risk underscore the importance of sex‐specific cognitive monitoring during ASCVD risk management and better vascular risk control in women to prevent cognitive decline.

1 September 2025 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
BQBaoshan Qiu
Baoshan Qiu
XCXueli Cai
Xueli Cai
LZLebo Zhou
Lebo Zhou
XWXuan Wang
Xuan Wang
SLShan Li
Shan Li
YWYilong Wang
Yilong Wang
BACKGROUND: The pathogenesis of atherosclerosis involves complex mechanisms, with inflammation playing a central role. Thromboinflammation may contribute to its development and progression. We investigated the association between circulating thromboinflammatory biomarkers and atherosclerotic plaques. METHODS: Participants aged 50 to 75 years from the baseline survey of the PRECISE study (Polyvascular Evaluation for Cognitive Impairment and Vascular Events) were included. Serum levels of thromboinflammatory biomarkers (sGPVI [soluble glycoprotein VI]; sADAMTS13 [soluble a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13]; and sP-selectin) were assessed by ELISA and Luminex assays and categorized into quartiles based on their empirical distribution within the study population. Eligible participants underwent imaging using computed tomography angiography and magnetic resonance imaging for coronary atherosclerosis, intracranial atherosclerosis, and extracranial atherosclerosis, respectively. RESULTS: A total of 3019 participants (mean age, 61.20±6.68 years; 46.47% male) were analyzed. After multivariable adjustment, participants in the fourth quartile of sGPVI levels had higher odds of coronary atherosclerotic plaque burden (common odds ratio, 1.42 [95% CI, 1.14–1.76]; P =0.0017). Conversely, those in the highest sADAMTS13 quartile had lower odds of coronary plaques (odds ratio, 0.75 [95% CI, 0.60–0.93]; P =0.0094), as well as reduced coronary plaque burden, including segment involvement score (common odds ratio, 0.75 [95% CI, 0.61–0.93]; P =0.0087) and segment stenosis score (common odds ratio, 0.75 [95% CI, 0.61–0.93]; P =0.0086). No significant associations were observed between sGPVI or sADAMTS13 levels and intracranial or extracranial atherosclerosis. Likewise, after multivariable adjustment, no significant associations were observed between sP-selectin (soluble P-selectin) levels and coronary, intracranial, or extracranial atherosclerosis. CONCLUSIONS: In our study, serum sADAMTS13 levels showed a negative association with both the presence and burden of coronary atherosclerosis, while sGPVI levels showed a positive association with the burden of coronary atherosclerosis. However, significant associations between the level of thromboinflammatory biomarkers, intracranial atherosclerosis, and extracranial atherosclerosis were not found.

28 July 2026 in Neurology
Verified
Journal Article
Closed access
YPYuesong Pan
Yuesong Pan
YGYing Gao
Ying Gao
WCWeiqi Chen
Weiqi Chen
SJS. Claiborne Johnston
S. Claiborne Johnston
PAPierre Amarenco
Pierre Amarenco
YWYilong Wang
Yilong Wang
Previous studies have shown a beneficial effect of clopidogrel-aspirin and intensive statin therapy in acute ischemic stroke; however, the synergistic effect of the 2 treatments is still unclear. The aim of this study was to investigate the effect of combining clopidogrel-aspirin and immediate intensive statin in patients with acute mild ischemic stroke or transient ischemic attack (TIA). We performed a multicenter, randomized, double-blind, placebo-controlled trial with a 2-by-2 factorial design across 222 hospitals in China. Eligible participants were patients with acute mild ischemic stroke or TIA of a presumed atherosclerotic cause within 72 hours of symptom onset. Patients were randomly assigned to receive clopidogrel plus aspirin or aspirin alone and an immediate or delayed intensive statin. The primary efficacy outcome was a new stroke (ischemic or hemorrhagic) within 90 days, and the primary safety outcome was moderate-to-severe bleeding. Between September 17, 2018, and October 15, 2022, 6,100 patients were enrolled (median age, 65 years; 64.2% male), of whom 1,525 each were assigned to the 4 groups. New stroke within 90 days occurred in 116 patients (7.6%) in the clopidogrel-aspirin plus immediate intensive statin group (hazard ratio [HR] 0.76, 95% CI 0.60-0.97), in 106 patients (7.0%) in the clopidogrel-aspirin plus delayed statin group (HR 0.69, 95% Cl 0.54-0.89), and in 129 patients (8.5%) in the aspirin plus immediate statin group (HR 0.85, 95% Cl 0.67 to 1.07), compared with 150 patients (9.9%) in the aspirin plus delayed intensive statin group. Moderate-to-severe bleeding occurred in 17 (1.1%) in the clopidogrel-aspirin plus immediate statin group (p = 0.047), 10 (0.7%) in the clopidogrel-aspirin plus delayed statin group (p = 0.46), and 6 (0.4%) in the aspirin plus immediate statin group (p = 0.80), compared with 7 (0.5%) in the aspirin plus delayed statin group. Among patients with mild ischemic stroke or TIA of presumed atherosclerotic cause, the combination of clopidogrel-aspirin and delayed intensive statin was superior to aspirin plus delayed intensive statin in reducing the risk of new stroke, an effect that was mainly driven by clopidogrel-aspirin and not significantly different from that of clopidogrel-aspirin plus immediate statin. The combination treatment had a low but increased risk of moderate-to-severe bleeding. ClinicalTrials.gov identifier: NCT03635749. This study provides Class I evidence that in patients with mild ischemic stroke or TIA of presumed atherosclerotic cause, the combination of clopidogrel-aspirin plus delayed intensive statin was superior to aspirin plus delayed intensive statin in reducing the 90-day risk of new stroke.